US-based Sagent Pharmaceuticals has introduced propofol injectable emulsion USP 1%, in two single-dose, single-patient vial presentations of 20mL and 100mL.
The company said that a 50mL single-dose, single-patient vial presentation will be launched shortly.
Sagent CEO and chairman of the board Jeffrey Yordon said the company has a strong commitment to responding to its customers' needs by providing an extensive portfolio of injectable pharmaceutical products.
"One challenge many customers face is maintaining adequate supply of certain key products that are only available from a limited number of sources," Yordon.
"Sagent has again fulfilled its commitment to our customers by becoming an alternative supplier of Propofol."
Sagent is mainly focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
The company has also created a global network of resources, including rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfils the evolving needs of patients.
